RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Acute LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Cytarabine

RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).

Trial Locations (1)

Unknown

RECRUITING

Peking University, Institute of Hematolgoy, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER